We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

228 hedge funds and large institutions have $1.54B invested in Collegium Pharmaceutical in 2024 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 78 increasing their positions, 78 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

453% more call options, than puts

Call options by funds: $3.33M | Put options by funds: $601K

225% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 16

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

24% more capital invested

Capital invested by funds: $1.24B → $1.54B (+$300M)

18% more funds holding

Funds holding: 193228 (+35)

0.71% more ownership

Funds ownership: 123.34%124.05% (+0.71%)

0% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 78

Holders
228
Holders Change
+35
Holders Change %
+18.13%
% of All Funds
3.28%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
52
Increased
78
Reduced
78
Closed
16
Calls
$3.33M
Puts
$601K
Net Calls
+$2.73M
Net Calls Change
+$4.57M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$228M +$2.76M +78,906 +1%
EAM
2
Eventide Asset Management
Massachusetts
$102M +$125K +3,563 +0.1%
Pacer Advisors
3
Pacer Advisors
Pennsylvania
$100M +$14.4M +412,110 +19%
Vanguard Group
4
Vanguard Group
Pennsylvania
$90.5M +$628K +17,942 +0.8%
RCMNY
5
Rubric Capital Management (New York)
New York
$71.2M -$32.3M -924,226 -34%
Invesco
6
Invesco
Georgia
$63.3M +$6.65M +190,039 +13%
Principal Financial Group
7
Principal Financial Group
Iowa
$60.3M -$570K -16,294 -1%
Renaissance Technologies
8
Renaissance Technologies
New York
$55.1M +$1.18M +33,600 +2%
State Street
9
State Street
Massachusetts
$51.2M +$181K +5,180 +0.4%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$39.6M -$702K -20,070 -2%
Fuller & Thaler Asset Management
11
Fuller & Thaler Asset Management
California
$37.6M +$33.9M +969,199 New
CCM
12
Camber Capital Management
Massachusetts
$33.1M -$6.9M -197,100 -19%
Morgan Stanley
13
Morgan Stanley
New York
$32.5M -$40.8M -1,166,558 -58%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$28.5M +$79.8K +2,282 +0.3%
EA
15
Emerald Advisers
Pennsylvania
$26M +$120K +3,416 +0.5%
Massachusetts Financial Services
16
Massachusetts Financial Services
Massachusetts
$25.7M -$116K -3,320 -0.5%
Janus Henderson Group
17
Janus Henderson Group
United Kingdom
$21.9M -$2.24M -64,107 -10%
RSCM
18
Rock Springs Capital Management
Maryland
$21.8M
Victory Capital Management
19
Victory Capital Management
Texas
$20.4M -$6.9M -197,334 -27%
EMFAT
20
Emerald Mutual Fund Advisers Trust
Pennsylvania
$19.8M -$1.42M -40,593 -7%
Northern Trust
21
Northern Trust
Illinois
$14.9M -$589K -16,828 -4%
LSV Asset Management
22
LSV Asset Management
Illinois
$14.8M +$8.7M +248,751 +189%
APM
23
Avidity Partners Management
Texas
$14M +$1.29K +37 +0%
Charles Schwab
24
Charles Schwab
California
$13.2M +$1.22M +34,967 +11%
Federated Hermes
25
Federated Hermes
Pennsylvania
$12.8M +$4.09M +116,763 +55%

COLL Hedge Fund Activity: Q1 2024 in Review

228 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2024, worth a combined $1.54B — up 24% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new COLL positions and 16 closed out — a net gain of 36 holders — while 78 added to existing stakes and 78 trimmed.

The largest buyer was Fuller & Thaler Asset Management, opening a new position worth an estimated $33.9M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.

  • 228 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2024, up from 193 in Q4 2023.
  • Funds reported $1.54B of Collegium Pharmaceutical stock for Q1 2024, up 24% quarter-over-quarter.
  • 52 funds opened new Collegium Pharmaceutical positions in Q1 2024 and 16 closed out, a net change of +36 holders.
  • The largest Collegium Pharmaceutical buyer in Q1 2024 was Fuller & Thaler Asset Management, an estimated $33.9M added.
  • The largest Collegium Pharmaceutical seller in Q1 2024 was Morgan Stanley, an estimated $40.8M sold.

Based on aggregated 13F filings for Q1 2024.